|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Motor_Neurone_Disease
|
|
gptkbp:activities
|
free radical scavenger
|
|
gptkbp:appointed_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:2017
gptkb:Japan
gptkb:United_States
|
|
gptkbp:class
|
phenolic compound
|
|
gptkbp:clinical_trial
|
gptkb:Japan
gptkb:United_States
Phase III
neuroprotective agent
improved function in ALS patients
reduced disability progression
|
|
gptkbp:contraindication
|
severe renal impairment
hypersensitivity to edaravone
|
|
gptkbp:developed_by
|
gptkb:Mitsubishi_Tanabe_Pharma_Corporation
|
|
gptkbp:discovered_by
|
gptkb:Japan
|
|
gptkbp:dissolved
|
water-soluble
|
|
gptkbp:duration
|
up to 14 days
|
|
gptkbp:education
|
importance of adherence
|
|
gptkbp:events
|
monitor liver function
|
|
gptkbp:financial_performance
|
light-sensitive
|
|
gptkbp:formulation
|
injectable solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Edaravone
|
|
gptkbp:ingredients
|
C10 H10 N2 O5 S
|
|
gptkbp:interacts_with
|
none significant
|
|
gptkbp:is_atype_of
|
N06 B X16
|
|
gptkbp:is_used_for
|
gptkb:amyotrophic_lateral_sclerosis
acute ischemic stroke
|
|
gptkbp:launch_date
|
gptkb:2017
|
|
gptkbp:lifespan
|
4 to 6 hours
|
|
gptkbp:manager
|
intravenous
|
|
gptkbp:market
|
ongoing monitoring
|
|
gptkbp:marketed_as
|
gptkb:Radicava
|
|
gptkbp:packaging
|
single-use vials
|
|
gptkbp:pharmacokinetics
|
antioxidant activity
rapid distribution
monitoring adverse effects
|
|
gptkbp:population
|
adults
|
|
gptkbp:provides_information_on
|
recommended for ALS
|
|
gptkbp:receives_funding_from
|
government and private sectors
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
PMDA
|
|
gptkbp:research_focus
|
gptkb:psychologist
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
gptkb:fandom
headache
bruising
liver enzyme elevation
skin rash
thrombocytopenia
hypotension
gait disturbance
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:type_of
|
57413-84-0
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:weight
|
250.26 g/mol
|